Sensible Biotechnologies: Series A

The business

Sensible secured $47 million in financing, including a Series A led by Oxford Science Enterprises and up to $20 million in non-dilutive funding. The company said the capital will scale its VECTOR platform and clinical-grade manufacturing, with the aim of extending mRNA technology beyond vaccines into other medicines.

Funding history

Oct 6, 2026Series A · This round$47M

Sources

Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform and Unlock Next Generation of mRNA Medicines - BioSpacebiospace.com · Oct 6, 2026

Similar rounds

All Biotech rounds →

WhiteLab Genomics

WhiteLab Genomics uses AI to design genetic medicines and develop bio-assets for cell, RNA and DNA therapies.

$26MSeries B · Oct 6, 2026

Autopoiesis Sciences

Autopoiesis Sciences is developing AI research tools that help scientists plan and carry out scientific discovery.

$11MSeed · Oct 6, 2026

Aventix

Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.

€1.2MPre-seed · Sep 30, 2026

AnaCardio

AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.

€62.5MSeries B · Sep 30, 2026

The business

Funding history

Sources

Similar rounds

Related